DermWire | Newest Articles http://practicaldermatology.com/dermwire/ Newest Articles en-us Mon, 18 Feb 2019 21:42:41 GMT Mon, 18 Feb 2019 21:42:41 GMT DermWire Dermatology Drugs Market to Reach $34.5 Billion by 2023 http://practicaldermatology.com/dermwire/view.asp?url=dermatology-drugs-market-to-reach-345-billion-by-2023 The dermatology drugs market is expected to reach $34.5 billion by 2023, a new report suggests. Research and Markets says that, among topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, and others, biologics are expected to be the fastest growing category, advancing at CAGR of 9.1% during the forecast period. The dermatology drugs market saw the highest revenue generated from psoriasis drugs during the historical period evaluated. The categ… Fri, 15 Feb 2019 04:00:00 GMT FDA Proposes Policy for New Competitive Generic Therapies Pathway http://practicaldermatology.com/dermwire/view.asp?url=fda-proposes-policy-for-new-competitive-generic-therapies-pathway The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their generic drug when there is not more than one approved drug in the active section of the Orange Book. The designation, established by Congress in the FDA Reauthorization Act of 2017, provides certain incentives fo… Fri, 15 Feb 2019 04:00:00 GMT New Guidelines Offer SRT Treatment Recommendations for Skin Cancers, Keloids http://practicaldermatology.com/dermwire/view.asp?url=new-guidelines-offer-srt-treatment-recommendations-for-skin-cancers-keloids Superficial Radiation Therapy (SRT) should be first-line therapy for appropriate non-melanoma skin cancers in appropriate patients, according to new consensus guidelines published in The Journal of Clinical and Aesthetic Dermatology. Appropriate tumor types for SRT include primary basal cell carcinoma and squamous cell carcinoma (SCC), significant SCC in situ and certain cases of cutaneous lymphomas and Kaposi sarcoma, the guidelines state. In addition, a consensus was reached on various … Thu, 14 Feb 2019 04:00:00 GMT Rodan Fields Takes on Teen Acne with Spotless http://practicaldermatology.com/dermwire/view.asp?url=rodan--fields-takes-on-teen-acne-with-spotless Rodan & Fields is launching Spotless, a patent-pending teen and young adult acne solution. The company is also updating its Unblemish Regimen with new formulas that feature Benzoyl Peroxide and Salicylic Acid. A two-step system, Spotless features a BPO2 Technology, a liquid form of Benzoyl Peroxide to get through the skin's biofilms, helping to bring the microbiome inside the pores back to balance. "Working side-by-side with our team of scientists and innovators we've pion… Thu, 14 Feb 2019 04:00:00 GMT Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removal http://practicaldermatology.com/dermwire/view.asp?url=sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red and light brown hair, SNA-001 demonstrated up to a 31 percent reduction of light hair from baseline. The data show that SNA-001 met the primary endpoint of non-inferiority in hair reduction (-17.5 pe… Wed, 13 Feb 2019 04:00:00 GMT Study Shows 97% Cure Rate for Superficial Radiation Therapy for BCC and SCC http://practicaldermatology.com/dermwire/view.asp?url=study-shows-97-cure-rate-for-superficial-radiation-therapy-for-bcc-and-scc A new retrospective study shows a high cure rate exceeding 97 percent among older patients (mean age: 82.5 years) being treated for basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) on their lower extremities with SRT-100TM Superficial Radiation Therapy from Sensus Healthcare. The article, “Superficial Radiation Therapy: A Viable Nonsurgical Option for Treating Basal and Squamous Cell Carcinoma of the Lower Extremities” appears in the February issue of the Journal of D… Wed, 13 Feb 2019 04:00:00 GMT Two New Psoriasis Guidelines Address Comorbidities, Biologic Treatment http://practicaldermatology.com/dermwire/view.asp?url=two-new-psoriasis-guidelines-address-comorbidities-biologic-treatment The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines outlining best practices for treating psoriasis with a focus on comorbidities and biologic treatment. Developed by an expert workgroup composed of several dermatologists, as well as a cardiologist, a rheumatologist and patient representatives, the guidelines appear in the Journal of the American Academy of Dermatology. One guideline focuses on the other health conditions that may be a… Wed, 13 Feb 2019 04:00:00 GMT Stelatopia Emollient Face Cream Now Available from Mustela http://practicaldermatology.com/dermwire/view.asp?url=stelatopia-emollient-face-cream-now-available-from-mustela Mustela Stelatopia Emollient Face Cream is now available, specifically designed for extremely dry to eczema-prone skin and gentle enough to use on newborns. Formulated with Avocado Perseose®, which is intended to restore and protect the skin barrier by boosting ceramides and hyaluronic acid, the cream moisturizes, replenishes, and soothes itchy skin. It protects from environmental aggressors with immediate and long-lasting hydration. The formulation also includes Sunflower Oil Distilla… Tue, 12 Feb 2019 04:00:00 GMT FDA Grants 510(k) Clearance to Laseroptek’s PicoLO http://practicaldermatology.com/dermwire/view.asp?url=fda-grants-510k-clearance-to-laseropteks-picolo- Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pulse duration producing strong photomechanical forces within the skin to breakdown and fragment pigments such as those found in tattoos. In addition, PicoLO incorporates Laseroptek 's patented Diffractive Optical Element (DOE) fractional technolo… Tue, 12 Feb 2019 04:00:00 GMT Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rx http://practicaldermatology.com/dermwire/view.asp?url=applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s novel TAAR receptor agonist reduces the force exerted by the ponytail on hair follicles; thus, reducing the likelihood of traction alopecia. "China is the world's second largest hair market. We are excited to team with the Hairmore Group, China&… Tue, 12 Feb 2019 04:00:00 GMT Lutronic Genius RF Microneedling Platform Cleared by FDA http://practicaldermatology.com/dermwire/view.asp?url=lutronic-genius-rf-microneedling-platform-cleared-by-fda Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care™products incorporate “smart” features to help practitioners provide outstanding care. “The Genius system is the best system that Lutronic has come up with,” shares E. Victor Ross, MD, Director Laser and Cosmetic Center at Scripps Clinic San Diego,… Tue, 12 Feb 2019 04:00:00 GMT MedPharm Ltd. Expands Partnership with Palvella Therapeutics, Inc. for PC Treatment http://practicaldermatology.com/dermwire/view.asp?url=medpharm-ltd-expands-partnership-with-palvella-therapeutics-inc-for-pc-treatment MedPharm Ltd, is expanding its partnership with Palvella Therapeutics, Inc. MedPharm has employed its formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study. “MedPharm is ver… Mon, 11 Feb 2019 04:00:00 GMT International Awards for Social Responsibility in Dermatology Calls for Submissions http://practicaldermatology.com/dermwire/view.asp?url=international-awards-for-social-responsibility-in-dermatology-calls-for-submissions Applications are being accepted online for the 2019 International Awards for Social Responsibility in Dermatology. This third edition of the Awards will recognize social initiatives led by dermatologists having a positive impact on patients and people facing dermatological issues in three main categories: Prevention and education on skin health Improved quality of life and self-esteem Access to care, coverage and surgery. The project must fall within the scope of a social init… Mon, 11 Feb 2019 04:00:00 GMT Combination Surgical Excision/Laser Treatment Improves Outcomes, Patient Satisfaction for CMN http://practicaldermatology.com/dermwire/view.asp?url=combination-surgical-excisionlaser-treatment-improves-outcomes-patient-satisfaction-for-cmn Combining lasers with surgical excision produces cosmetically superior results compared to laser-only treatments for small to medium congenital melanocytic nevi (CMN), according to a new review. The report appears in Lasers in Surgery and Medicine (LSM). It was selected as Editor’s Choice in the January 2019 issue of LSM. Researchers retrospectively reviewed 119 cases of small to medium-sized CMN. Treatment options were categorized into four groups: (i) Excision only; (ii) Excision f… Mon, 11 Feb 2019 04:00:00 GMT Immunotherapy Appears Better Than Chemotherapy for Aggressive Merkle Cell Carcinoma http://practicaldermatology.com/dermwire/view.asp?url=immunotherapy-appears-better-than-chemotherapy-for-aggressive-merkle-cell-carcinoma First-line therapy with Pembrolizumab may produce better responses and result in longer survival in Merkel cell carcinoma than conventional chemotherapy. The study, co-led by Suzanne Topalian, M.D., associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center, is the longest observation to date of Merkel cell carcinoma patients treated with any anti-PD-1 immunotherapy drug used in the first line. The findings, published in the Journal… Fri, 8 Feb 2019 04:00:00 GMT New from BD: Prefillable Glass Syringe for Viscous Solutions http://practicaldermatology.com/dermwire/view.asp?url=new-from-bd-prefillable-glass-syringe-for-viscous-solutions BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillable syringe that is validated for delivery of intravenous drugs. It is compatible with main IV connectors and can be used for various indications. BD Hylok LLA (luer-lok adaptor) is strongly affixed, using new bonding technology, and reduces the risk of LLA r… Thu, 7 Feb 2019 04:00:00 GMT Key West Bans Sunscreens with Oxybenzone and Octinoxate http://practicaldermatology.com/dermwire/view.asp?url=key-west-bans-sunscreens-with-oxybenzone-and-octinoxate Following Hawaii’s lead, Florida’s Key West City Commission voted to ban the sale of products that contain oxybenzone or octinoxate -- two chemicals in sunscreen that have been shown to wash off and potentially damage coral reefs. The ban takes effect in January 2021. First-time offenders will receive a written warning and after that, violations will follow the city's standard civil citation procedures, according to media reports. "To me, it boils right down to the f… Thu, 7 Feb 2019 04:00:00 GMT Study Finds Lack of Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations http://practicaldermatology.com/dermwire/view.asp?url=study-finds-lack-of-disclosure-of-potential-conflicts-of-interest-in-dermatology-patient-advocacy-organizations A recent study published in JAMA Dermatology was conducted to examine potential financial conflicts of interest and characterize disclosure practices among dermatology patient advocacy organizations. For this cross-sectional study of the largest dermatology patient advocacy organizations, researchers used the Kaiser Health News database to acquire data on total revenue from each organization’s Form 990 for the year 2015. Tax forms and annual reports from 2017 were used for 2 organizatio… Wed, 6 Feb 2019 04:00:00 GMT Biologics May Reduce Plaque Buildup in Psoriasis Patients’ Arteries http://practicaldermatology.com/dermwire/view.asp?url=biologics-may-reduce-plaque-buildup-in-psoriasis-patients-arteries Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the National Heart, Lung, and Blood Institute (NHLBI) that appears online today in the journal Cardiovascular Research. “Classically a heart attack is caused by one of five risk factors: diabetes, hypertension, high cholesterol, family history, or smoking,” says Nehal N. Mehta, M.D., head of the … Tue, 5 Feb 2019 04:00:00 GMT Jeuveau from Evolus Now FDA Cleared for Aesthetic Injection http://practicaldermatology.com/dermwire/view.asp?url=jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this spring. “Evolus is the first company in nearly a decade to enter the fast-growing US aesthetic neurotoxin market. What makes Evolus unique is our focus on delivering performance beauty products w… Sat, 2 Feb 2019 04:00:00 GMT Dr. Adam Friedman to Serve as Interim Chair of GW’s Department of Dermatology http://practicaldermatology.com/dermwire/view.asp?url=dr-adam-friedman-to-serve-as-interim-chair-of-gws-department-of-dermatology The GW School of Medicine and Health Sciences (SMHS) and the GW Medical Faculty Associates (GW MFA) have selected Adam Friedman, MD, FAAD, professor of dermatology, to serve as the interim chair of the GW Department of Dermatology. He assumed the role on Jan. 31, 2019. Alison Ehrlich, MD, MHS, professor of dermatology and the founding chair of the current Department of Dermatology at GW in 2012, has stepped down from the chair position to rejoin the clinical faculty. "I am grateful to… Fri, 1 Feb 2019 04:00:00 GMT Dr. Alice Gottlieb to Share Hidradenitis Suppurativa Findings at AAD Annual Meeting http://practicaldermatology.com/dermwire/view.asp?url=dr-alice-gottlieb-to-share-hidradenitis-suppurativa-findings-at-aad-annual-meeting Alice Gottlieb, MD, PhD will be presenting “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2, 2019 at the American Academy of Dermatology annual meeting being held at the Walter E. Washington Convention Center in Washington, DC. The presentation, which was accepted as “late-breaking research: clinical trials,” will provide details of XBiotech's recent Phase 2 clinical tria… Fri, 1 Feb 2019 04:00:00 GMT Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meeting http://practicaldermatology.com/dermwire/view.asp?url=menlo-therapeutics-to-present-late-breaking-oral-presentation-at-aad-annual-meeting Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. The abstract, “Serlopitant Reduced Pruritus Associated with Psoriasis in Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial” will be presented as part of Late Breaking Research: Clinical Tri… Fri, 1 Feb 2019 04:00:00 GMT Vyome Secures $22M to Advance Dermatology Pipeline http://practicaldermatology.com/dermwire/view.asp?url=vyome-secures-22m-to-advance-dermatology-pipeline Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, closed $22 million in financing. The company says it plans to primarily use the funds to advance its lead molecule, VB 1953, through Phase 2 studies for treatment of moderate to severe acne, as well as for operations. Part of the funds raised are used for facilitating a secondary transaction. "The closing of Vyome's Series D co… Fri, 1 Feb 2019 04:00:00 GMT 2019 Residents of Distinction Return from Caribbean Dermatology Symposium http://practicaldermatology.com/dermwire/view.asp?url=2019-residents-of-distinction-return-from-caribbean-dermatology-symposium Five dermatology residents have just returned from the 18th Annual Caribbean Dermatology Symposium, held in Grand Cayman Island. Their participation was sponsored by Beiersdorf Inc., as part of the dermMentors™ Resident of Distinction Award™ program. The residents presented new scientific research during an independent mentoring session on Friday, January 18. Timothy Durso, MD, a third-year resident in dermatology at the San Antonio Uniformed Services Health Education Consortium,… Thu, 31 Jan 2019 04:00:00 GMT